



ACT EU MSP AG: group and mandate renewal

MSP AG 18 June 2026

Maria Filancia, Liaison specialist
European Medicines Agency





2025

Focused discussion on complex challenges, possible solutions and 3 focus groups set up.



2024

Start of group activities focusing on building trust and identification of 24 key priorities for the ACT EU workplan.





2026

Continuous discussion on key priorities and proposals while renewing group mandate and composition.



Overall approach

MSP AG composition, mandate and rules of procedures are subject to revision every 3 years.




18 June-30 September 2026: launch survey on group experience, mandate and rules of procedure.




September-October 2026:

- review preliminary feedback during the MSP AG meeting (17/09) and further discuss experience during annual meeting (22/10)
- launch call for expressions of interest to support the renewal of the group's composition (17/09-29/10).



November-December 2026: ACT EU Steering Group (SG) endorsement of revised group composition, mandate, rules of procedure.



March 2027: kick off of revised group composition, mandate and rules of procedure.

Feedback survey

Objective/scope

- Assess **stakeholder experience** across MSP AG representatives (permanent, alternate, ad hoc) with the organisations aspects and group dynamics and identify opportunity for improvement.
- Identify **opportunities to enhance** the mandate/rules of procedure.
- Ensure **constructive, effective, and inclusive engagement** with all stakeholders involved in ACT EU activities.

Current MSP AG composition revision

Composition

- 5 patients/consumers
- 4 healthcare professional
- 4 pharmaceutical industry
- 4 Non-commercial European clinical data and translational research organisations and networks
- 4 research funders

Approach

- Public call for expression of interest.
- Targeted mailing to all stakeholder groups.

Guiding criteria (mandate annex 2)

- **Legitimacy:** EU/EEA non-for-profit organisation with EU-wide representation/scope.
- **Activities:** clinical trial area/medicinal products.
- **Representation:** member representativeness mechanism.
- **Accountability:** Statements/opinion reflecting members views/opinion.
- **Sectors/areas of involvement:** e.g. medical device, biotechnology, general practitioners, public health promotion, learned/scientific societies, research consortia.

BUT use the feedback survey to highlight gaps that require to be addressed in terms of group composition!!

Thank you

misp-agsecretariat@ema.europa.eu

